Loading organizations...
Founded in 2022 by Simon Restrepo, Scott Fraser, and Kaspar Binz, arcoris bio is a company based in Schlieren, Switzerland, developing advanced spatial multiomics technologies and biomarker detection platforms. Its flagship MUSE platform provides universal, programmable signal amplification for highly sensitive multiplex assays, enabling scientists to analyze molecular data within the physical context of tissue samples. Operating a B2B model, the enterprise supplies research tools, in vitro diagnostics products, and analytical software to academic institutions, pharmaceutical companies, and clinical laboratories. These biomarker solutions are designed to advance digital pathology, accelerate drug discovery, and improve clinical diagnostics by providing deeper insights into cellular interactions and disease pathology. To industrialize this technology and expand commercial partnerships, the firm secured an oversubscribed seed round of 6,300,000 Swiss francs jointly led by Ventura Ace and ZEISS Ventures, alongside Zürcher Kantonalbank.
arcoris bio has raised $7.8M across 1 funding round.
arcoris bio has raised $7.8M in total across 1 funding round.
arcoris bio has raised $7.8M in total across 1 funding round.
arcoris bio's investors include Andreas Jenne, Benedikt Kläs, Zürcher Kantonalbank.
arcoris bio has raised $7.8M across 1 funding round. Most recently, it raised $7.8M Seed in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 6, 2025 | $7.8M Seed | Andreas Jenne, Benedikt Kläs | Zürcher Kantonalbank | Announced |
